European Blood Pressure Intensive Control After Stroke

PHASE2RecruitingINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Ischemic StrokeTransient Ischemic Attack
Interventions
OTHER

anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration

"A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly."

OTHER

Standard of Care Blood Pressure Management with Antihypertensives

Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.

Trial Locations (1)

Unknown

RECRUITING

Mater Misericordiae University Hospital, Dublin

All Listed Sponsors
collaborator

St Vincent's University Hospital, Ireland

OTHER

collaborator

Cork University Hospital

OTHER

collaborator

Tallaght University Hospital

OTHER

collaborator

HRB Stroke Trials Network Ireland

UNKNOWN

collaborator

National University of Ireland, Galway, Ireland

OTHER

collaborator

Mater Misericordiae University Hospital

OTHER

collaborator

St. James's Hospital, Ireland

OTHER

collaborator

Connolly Hospital Blanchardstown

OTHER

lead

University College Dublin

OTHER

NCT04647292 - European Blood Pressure Intensive Control After Stroke | Biotech Hunter | Biotech Hunter